Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. lowered its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 30.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,976 shares of the company’s stock after selling 12,568 shares during the period. Harbor Capital Advisors Inc.’s holdings in Verve Therapeutics were worth $132,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. BVF Inc. IL boosted its stake in Verve Therapeutics by 962.2% during the 4th quarter. BVF Inc. IL now owns 6,904,050 shares of the company’s stock worth $38,939,000 after purchasing an additional 6,254,050 shares during the period. Schonfeld Strategic Advisors LLC lifted its stake in shares of Verve Therapeutics by 57.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company’s stock worth $21,372,000 after acquiring an additional 1,382,176 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in shares of Verve Therapeutics by 18.5% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,848,071 shares of the company’s stock worth $10,423,000 after acquiring an additional 288,678 shares during the period. Geode Capital Management LLC lifted its stake in shares of Verve Therapeutics by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 1,625,780 shares of the company’s stock worth $9,172,000 after acquiring an additional 25,093 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Verve Therapeutics in the 4th quarter worth $7,863,000. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Stock Down 2.5%

Shares of NASDAQ VERV opened at $6.16 on Monday. Verve Therapeutics, Inc. has a 52 week low of $2.86 and a 52 week high of $9.31. The firm has a 50-day moving average price of $4.80 and a 200 day moving average price of $5.80. The stock has a market capitalization of $549.12 million, a price-to-earnings ratio of -2.50 and a beta of 1.67.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The firm had revenue of $32.98 million during the quarter, compared to analysts’ expectations of $7.13 million. Equities research analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Wall Street Zen upgraded shares of Verve Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Cantor Fitzgerald upgraded shares of Verve Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Tuesday, April 15th. HC Wainwright raised their target price on shares of Verve Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, April 14th. Royal Bank of Canada reduced their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, March 4th. Finally, Guggenheim raised their price objective on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, April 15th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $25.75.

Verve Therapeutics Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.